Tech Company Financing Transactions
Immunis Funding Round
Immunis, based in Irvine, secured $10 million in funding from Remiges Ventures and private investors.
Transaction Overview
Company Name
Announced On
8/10/2022
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Series A
Investors
Remiges Ventures (Lead Investor)
Proceeds Purpose
The company intends to use the funds to support clinical assessment of its immunomodulatory secretome product in an FDA-awarded Phase 1/2a clinical trial targeting muscle atrophy, which is an age, disuse and disease-associated condition experienced by 100% of the population.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
18301 Von Karman Ave.
Irvine, CA 92612
USA
Irvine, CA 92612
USA
Phone
Undisclosed
Website
Email Address
Overview
Immunis is a private biotechnology company focused on the development of treatments for age-related and disease-related immune deficits. Immunis has developed a novel method to grow human stem cells for clinical use, and direct them to become highly pure populations of defined cells that secrete factors which benefit immune system development, modulation, and health.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Hans Keirstead
Chief Scientific Officer
Tom Lane
VP - Operations
Joelle Hafen
VP - Regulatory Affairs
Erin Curry
Browse more venture capital transactions:
Prev: 8/10/2022: Maximus venture capital transaction
Next: 8/10/2022: TeamApt venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs